Dextran-engineered Cu-MOF nanozyme with multi-enzyme mimetic cascade for cuproptosis-enhanced synergistic therapy in
Yu-E Wang1, Hong Yang2, Shibo Zhao2
1The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability, Guizhou Medical University, NO. 6 Ankang avenue, Guian New District, 561113, Guizhou, China; The State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmaceutical Sciences, Guizhou Medical University, NO. 6 Ankang avenue, Guian New District, 561113, Guizhou, China; Department of Cardiovascular Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Beijing Road, Yunyan District, Guiyang 550025, China.
Abstract:
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options. To address this challenge, we reported a novel multifunctional copper-based metal-organic framework (Cu-MOF) nanozyme, D@D@MOF, for targeted cascade catalytic therapy and synergistic induction of cuproptosis in TNBC. The Cu-MOF, synthesized via coordination of aminotriazole (3-AT) and copper, serves as a catalytic center, while disulfiram (DSF) is encapsulated for therapeutic synergy. Surface modification with dextran (DEX), a glucose-based polysaccharide, enhances tumor targeting through interactions with overexpressed glucose transporter protein 1 (GLUT1) on cancer cells, while improving stability and biocompatibility. D@D@MOF exhibits peroxidase (POD)-like, superoxide dismutase (SOD)-like, and glutathione peroxidase (GPx)-like activities, activated specifically in the TME. These cascade catalytic reactions significantly elevated reactive oxygen species (ROS) levels and deplete glutathione (GSH), inducing intense oxidative stress and cuproptosis. The incorporation of 3-AT amplifies oxidative stress by inhibiting catalase, while DSF reduction generates cytotoxic CuET, further enhancing cuproptosis. In vitro and in vivo studies confirm D@D@MOF's efficacy in tumor cell death via ROS amplification and GSH depletion, with minimal off-target effects. This work presents a TME-responsive nanoplatform for cascade catalytic therapy and introduces cuproptosis as a novel strategy for TNBC treatment, advancing the design of multifunctional nanozymes for cancer therapy.
